US Opens Section 301 Tariff Probe Into Germany Over Drug Pricing
Updated
Updated · Bloomberg · Jun 19
US Opens Section 301 Tariff Probe Into Germany Over Drug Pricing
1 articles · Updated · Bloomberg · Jun 19
Summary
Washington on Thursday night opened a Section 301 investigation into Germany, a step that can lead to retaliatory tariffs on German goods.
The probe targets what the US called Germany’s persistent underpayment for innovative pharmaceutical products, framing it as a burden shifted onto American patients.
U.S. Trade Representative Jamieson Greer said the action reflects President Trump’s view that Americans should not shoulder a disproportionate share of global pharmaceutical research-and-development costs.
Section 301 gives the US a formal trade tool to investigate alleged unfair foreign practices and, if it finds harm, impose levies in response.